VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.
Sher S, Whipp E, Walker J, Zhang P, Beaver L, Williams K, Orwick S, Ravikrishnan J, Walker B, Perry E, Gregory C, Purcell M, Pan A, Yan P, Alinari L, Johnson AJ, Frigault MM, Greer JM, Hamdy A, Izumi R, Mo X, Sampath D, Woyach J, Blachly J, Byrd JC, Lapalombella R.
Sher S, et al.
Leukemia. 2023 Feb;37(2):326-338. doi: 10.1038/s41375-022-01758-z. Epub 2022 Nov 14.
Leukemia. 2023.
PMID: 36376377
Free PMC article.